Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Non-Current Deffered Revenue (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Non-Current Deffered Revenue for 8 consecutive years, with $20.0 million as the latest value for Q3 2025.

  • Quarterly Non-Current Deffered Revenue fell 24.92% to $20.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $20.0 million through Sep 2025, down 24.92% year-over-year, with the annual reading at $23.3 million for FY2024, 68.12% down from the prior year.
  • Non-Current Deffered Revenue for Q3 2025 was $20.0 million at Precision Biosciences, down from $20.2 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $131.2 million in Q1 2021, with the low at $20.0 million in Q3 2025.
  • Average Non-Current Deffered Revenue over 5 years is $63.6 million, with a median of $73.1 million recorded in 2023.
  • The sharpest move saw Non-Current Deffered Revenue surged 99.05% in 2021, then tumbled 72.58% in 2025.
  • Over 5 years, Non-Current Deffered Revenue stood at $67.0 million in 2021, then grew by 23.66% to $82.9 million in 2022, then fell by 11.81% to $73.1 million in 2023, then plummeted by 68.12% to $23.3 million in 2024, then fell by 14.35% to $20.0 million in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $20.0 million, $20.2 million, and $20.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.